IL148916A0 - Design of high affinity rnase h recruiting oligonucleotide - Google Patents

Design of high affinity rnase h recruiting oligonucleotide

Info

Publication number
IL148916A0
IL148916A0 IL14891600A IL14891600A IL148916A0 IL 148916 A0 IL148916 A0 IL 148916A0 IL 14891600 A IL14891600 A IL 14891600A IL 14891600 A IL14891600 A IL 14891600A IL 148916 A0 IL148916 A0 IL 148916A0
Authority
IL
Israel
Prior art keywords
recruiting
rnase
oligonucleotide
design
high affinity
Prior art date
Application number
IL14891600A
Original Assignee
Exiqon As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon As filed Critical Exiqon As
Publication of IL148916A0 publication Critical patent/IL148916A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL14891600A 1999-10-04 2000-10-03 Design of high affinity rnase h recruiting oligonucleotide IL148916A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901422 1999-10-04
US15772499P 1999-10-05 1999-10-05
PCT/DK2000/000550 WO2001025248A2 (en) 1999-10-04 2000-10-03 Design of high affinity rnase h recruiting oligonucleotide

Publications (1)

Publication Number Publication Date
IL148916A0 true IL148916A0 (en) 2002-09-12

Family

ID=26065735

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14891600A IL148916A0 (en) 1999-10-04 2000-10-03 Design of high affinity rnase h recruiting oligonucleotide

Country Status (6)

Country Link
EP (1) EP1224280A2 (en)
JP (1) JP2003511016A (en)
AU (1) AU7406700A (en)
CA (1) CA2385853A1 (en)
IL (1) IL148916A0 (en)
WO (1) WO2001025248A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351077A1 (en) * 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
HUE037352T2 (en) 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As Oligomeric compounds for the modulation of hif-1alpha expression
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
AU2015204315B2 (en) * 2002-11-18 2017-06-22 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
AU2013201786B2 (en) * 2002-11-18 2015-04-02 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP2284269B1 (en) * 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
RU2377301C2 (en) 2003-12-23 2009-12-27 Сантарис Фарма А/С OLIGOMER COMPOUND REDUCING EXPRESSION OF HUMAN GENE Bcl-2, CONJUGATE, PHARMACEUTICAL COMPOSITION AND APPLICATION OF OLIGOMER COMPOUND IN CANCER TREATMENT
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
KR20070095882A (en) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Lna oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP2338991B1 (en) 2005-08-29 2017-01-18 Regulus Therapeutics Inc. Methods for use in modulating MIR-122a
DK1931780T3 (en) * 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
EP3000480A1 (en) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
ES2556128T3 (en) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S Internally segmented small interfering RNA
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG170773A1 (en) 2006-04-03 2011-05-30 Santaris Pharma As Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US7884194B2 (en) 2007-06-06 2011-02-08 Avi Biopharma Inc. Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
EP2183360B1 (en) 2007-08-30 2017-01-11 Hadasit Medical Research Services&Development Company Ltd. Nucleic acid sequences comprising nf-(kappa)b binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders
DK2623599T3 (en) 2007-10-04 2019-04-08 Roche Innovation Ct Copenhagen As Micromirers
EP2212437A4 (en) 2007-11-07 2011-09-28 Univ British Columbia Microfluidic device and method of using same
AU2009221064B2 (en) 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
KR20130137160A (en) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 Single-stranded rnai agents containing an internal, non-nucleic acid spacer
DK2756080T3 (en) 2011-09-14 2019-05-20 Translate Bio Ma Inc MULTIMERIC OILONCLEOTID CONNECTIONS
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US20150299803A1 (en) 2012-11-05 2015-10-22 Pronai Therapeutics, Inc. Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
CN117126846A (en) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 Oligonucleotide conjugates
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
RU2649367C2 (en) * 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Lna oligonucleotide carbohydrate conjugates
MX371093B (en) 2013-05-01 2020-01-16 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122.
TWI680767B (en) 2013-05-01 2020-01-01 美商雷格勒斯治療公司 Compounds and methods for enhanced cellular uptake
BR112015032432B1 (en) 2013-06-27 2023-02-07 Roche Innovation Center Copenhagen A/S ANTI-SENSE OLIGOMER, ANTI-SENSE OLIGONUCLEOTIDE CONJUGATES, PHARMACEUTICAL COMPOSITION, USE THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA OR RELATED DISORDERS, AND IN VITRO METHOD FOR REDUCING THE EXPRESSION LEVELS AND/OR THE ACTIVITY OF PCSK9 IN A CELL
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
EP3099798B1 (en) 2014-01-29 2018-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
AU2015318782A1 (en) 2014-09-18 2017-04-06 The University Of British Columbia Allele-specific therapy for Huntington Disease haplotypes
WO2018024849A1 (en) 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
US11261445B2 (en) 2017-10-17 2022-03-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination treatment for cystic fibrosis
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
IT201900017234A1 (en) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA for the treatment of leiomyoma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
IL299771A (en) 2020-07-10 2023-03-01 Inst Nat Sante Rech Med Methods and compositions for treating epilepsy
WO2022174113A1 (en) 2021-02-12 2022-08-18 Merand Pharmaceuticals, Inc. Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
WO2022200632A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-134 inhibitors
BR112023019582A2 (en) 2021-03-26 2023-12-05 Neumirna Therapeutics Aps MICRORNA-27B INHIBITOR ANTISENSE OLIGONUCLEOTIDE
WO2022254021A1 (en) 2021-06-04 2022-12-08 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
JP2024531363A (en) 2021-08-17 2024-08-29 コリア アドバンスト インスティテュート オブ サイエンス アンド テクノロジー Antisense oligonucleotides targeting the Cav3.1 gene and uses thereof
AU2022329462A1 (en) 2021-08-19 2024-03-28 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
WO2024146935A1 (en) 2023-01-06 2024-07-11 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain
EP4450626A1 (en) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Fnip2 inhibitors for treating ataxia telangiectasia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
KR100414936B1 (en) * 1997-09-12 2004-01-13 엑시콘 에이/에스 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues

Also Published As

Publication number Publication date
EP1224280A2 (en) 2002-07-24
WO2001025248A2 (en) 2001-04-12
CA2385853A1 (en) 2001-04-12
JP2003511016A (en) 2003-03-25
AU7406700A (en) 2001-05-10
WO2001025248A3 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
IL148916A0 (en) Design of high affinity rnase h recruiting oligonucleotide
IL149694A0 (en) Therapeutic uses of lna-modified oligonucleotides
HUP0105367A3 (en) Novel nucleosides and oligonucleotide analogues
TW413158U (en) Steel ball pen
AU2002350631A1 (en) Phosphorothioate-modified oligonucleotide as anti-restenosis agent
EP1193082A4 (en) Ball for ball-point pen and ball-point pen
AU7737300A (en) Dna-cleaving rnase p rna
DE69833112D1 (en) Rna polymerase
IL149599A0 (en) Use of disease-associated gene
EP1222212A4 (en) Il13 mutants
AU3352400A (en) Axial ball transfer assemblies
IL146332A0 (en) PrP-LIKE GENE
AU7309500A (en) Metal cluster containing nucleotides and nucleic acids, and intermediates therefor
GB9915036D0 (en) Method of imputting text
GB9909325D0 (en) Pen nib
EP0974652A4 (en) Cancerous metastasis-associated gene
EP1076093A4 (en) Sakuranetin synthase gene
GB9900215D0 (en) Structure of vehicles
GB9922125D0 (en) Phosphodiesterase enzymes
GB9924981D0 (en) Gene therapy
AU7064500A (en) Human narcolepsy gene
GB9900009D0 (en) Gene therapy
AU4808200A (en) Dna balls
GB9905644D0 (en) Dna
EP1182266A4 (en) Cyp2a6 gene judgment methods